Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Literature
1.
Yuan W, Xu L, Feng Y, Yang Y, Chen W, Wang J, Pang D, Li D (2010) The hOGG1 Ser326Cys polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 122:835–842PubMedCrossRef
2.
Zhang Y, Newcomb PA, Egan KM, Titus-Ernstoff L, Chanock S, Welch R, Brinton LA, Lissowska J, Bardin-Mikolajczak A, Peplonska B et al (2006) Genetic polymorphisms in base-excision repair pathway genes and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15:353–358PubMedCrossRef
3.
Romanowicz-Makowska H, Smolarz B, Makowski M, Polac I, Pertynski T (2008) Ser326Cys polymorphism in DNA repair genes hOGG1 in breast cancer women. Pol J Pathol 59:201–204PubMed
4.
Synowiec E, Stefanska J, Morawiec Z, Blasiak J, Wozniak K (2008) Association between DNA damage, DNA repair genes variability and clinical characteristics in breast cancer patients. Mutat Res 648:65–72PubMed
5.
Vogel U, Nexo BA, Olsen A, Thomsen B, Jacobsen NR, Wallin H, Overvad K, Tjonneland A (2003) No association between OGG1 Ser326Cys polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev 12:170–171PubMed
6.
Gu D, Wang M, Zhang Z, Chen J (2010) Lack of association between the hOGG1 Ser326Cys polymorphism and breast cancer risk: evidence from 11 case–control studies. Breast Cancer Res Treat 122:527–531PubMedCrossRef
1.
Zhang Y, Newcomb PA, Egan KM, Titus-Ernstoff L, Chanock S, Welch R, Brinton LA, Lissowska J, Bardin-Mikolajczak A, Peplonska B et al (2006) Genetic polymorphisms in base-excision repair pathway genes and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15:353–358PubMedCrossRef
2.
Vogel U, Nexo BA, Olsen A, Thomsen B, Jacobsen NR, Wallin H, Overvad K, Tjonneland A (2003) No association between OGG1 Ser326Cys polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev 12:170–171PubMed
3.
Gu D, Wang M, Zhang Z, Chen J (2010) Lack of association between the hOGG1 Ser326Cys polymorphism and breast cancer risk: evidence from 11 case-control studies. Breast Cancer Res Treat 122:527–531PubMedCrossRef
Metadata
Title
Lack of association between hOGG1 Ser326Cys polymorphism and breast cancer susceptibility in European population
Authors
Da-Peng Ding
Ying Zhang
Xiao-Feng He
Publication date
01-10-2011
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1571-6

Other articles of this Issue 3/2011

Breast Cancer Research and Treatment 3/2011 Go to the issue

Letter to the Editor

Data in a recent meta-analysis about TNF-alpha polymorphisms and breast cancer susceptibility need for clarification

Clinical trial

Excised and irradiated volumes in relation to the tumor size in breast-conserving therapy

Epidemiology

Patient and tumor characteristics of bilateral breast cancer at screening mammography in the Netherlands, a population-based study

Preclinical study

Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma

Clinical Trial

The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures

Preclinical study

SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits